



ASX ANNOUNCEMENT

Lumos secures follow-on contract with Aptatek Biosciences for development of Phenylketonuria (PKU) in-home monitoring device

Key Highlights

- Lumos secures follow-on contract to move PKU in-home monitoring device to next stage of clinical development and commercial readiness
- US\$1.5 million contract commencing September 2025, to be charged on time-and-materials basis
- PKU affects 1 in 12,000 newborns, leading to neurological complications if un-checked.

MELBOURNE, Australia (1 September 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, is pleased to announce it has secured a follow-on development contract with New Jersey-based Aptatek Biosciences, Inc. (Aptatek) to advance the PheCheck™ aptamer-based, in-home monitoring tool for the screening and management of phenylketonuria (PKU).

PKU is a rare inherited disorder affecting approximately 1 in 12,000 newborns. It causes a build-up of the amino acid phenylalanine in the body, which, if untreated, can lead to intellectual disabilities, seizures, behavioral issues, and mental health disorders. The Aptatek device, developed in collaboration with Lumos, is designed to enable PKU patients to measure their phenylalanine levels in real time from home or at the point of care, enabling faster detection and improved ongoing management. The product has been granted FDA Breakthrough Device designation, which is expected to expedite its regulatory review.

Lumos was first engaged by Aptatek in June 2022 following a competitive bidding process. The initial phase of the collaboration generated US\$0.5 million in revenue for Lumos and supported Aptatek’s pre-clinical studies designed to demonstrate the device’s performance and usability in the hands of end users.

With additional funding secured, Aptatek will now progress to the next stage to complete development and conduct formal verification and validation studies. Under the new contract, Lumos will focus on maturing the design of the tests, blood processing unit, and readers; conducting formal verification testing to ensure the device meets product requirements for clinical trials and FDA submission.

The contract, valued at approximately US\$1.5 million and charged on a time-and-materials basis, is expected to commence in September 2025 and run for around 10 months. Additional revenue opportunities are anticipated through Lumos support of clinical trials and ongoing instrument manufacturing in subsequent phases of the partnership.

"We are delighted to have selected Lumos once again as our partner in bringing the PheCheck™ aptamer-based In-home monitoring platform to market. PKU is a challenging condition for patients and families, and a reliable at-home monitoring tool has the potential to transform how it is managed, said Michael Boyce-Jacino, CEO of Aptatek Biosciences"

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *"We are pleased to extend our collaboration with Aptatek on this important program. Securing this follow-on contract reflects both the quality of our work to date and the trust Aptatek places in Lumos' expertise. We look forward to supporting Aptatek through the next critical stages of development and towards commercialization."*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Aptatek

Aptatek is a mobile health company developing innovative systems combining novel sensing technology and innovative digital health tools to enable detection and monitoring of small molecule targets on a portable platform. The privately held company is commercializing technology developed by Columbia scientists and licensed from Columbia University by Aptatek and is based in Princeton, New Jersey.

For more information visit aptatek.com.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
HACK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne, VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598